Publications by authors named "Deepan Chatterjee"
Article Synopsis
- Acquired resistance to targeted cancer therapies significantly contributes to patient mortality, prompting the need for better resistance modeling.
- The study introduces a 6-to-16-week assay for simulating acquired resistance in both adherent and suspension cancer cell lines, focusing on testing dosages and combination therapies.
- This protocol offers a high-throughput, scalable, and cost-effective approach for researching drug resistance, with full details available in referenced studies by Sealover et al. and Theard et al.
Small-cell lung cancer (SCLC) is designated a recalcitrant cancer due to its five-year relative survival rate of less than 7%. First line SCLC treatment has changed modestly in the last 40 years. The NeuroD1 subtype of SCLC (SCLC-N) commonly harbors MYC amplifications and other hallmarks of aggressive behavior.
View Article and Find Full Text PDFKRAS is the most commonly mutated oncogene. Targeted therapies have been developed against mediators of key downstream signaling pathways, predominantly components of the RAF/MEK/ERK kinase cascade. Unfortunately, single-agent efficacy of these agents is limited both by intrinsic and acquired resistance.
View Article and Find Full Text PDF